---
title: "Windtree Therapeutics Sells Cardiovascular Drug Candidates to Seismic Pharmaceutical Holdings"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/270624532.md"
datetime: "2025-12-23T14:01:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270624532.md)
  - [en](https://longbridge.com/en/news/270624532.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270624532.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/270624532.md) | [English](https://longbridge.com/en/news/270624532.md)


# Windtree Therapeutics Sells Cardiovascular Drug Candidates to Seismic Pharmaceutical Holdings

Windtree Therapeutics has entered into an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC. Under the terms of the deal, Windtree will receive 20% of any milestone payments, royalties, or similar economic interests, including all global commercial net revenues generated from the cardiovascular assets. In addition, Windtree will be eligible for a $700,000 payment if Seismic completes a financing round of at least $10 million. The agreement also includes the transfer of certain cardiovascular development payables from Windtree to Seismic, relieving Windtree of future funding obligations for the development of these drug candidates. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Windtree Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9616559) on December 23, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### 相關股票

- [Windtree Therapeutics (WINT.US)](https://longbridge.com/zh-HK/quote/WINT.US.md)

## 相關資訊與研究

- [BNB coin price jumps following Windtree Therapeutics’ $200M BNB Treasury launch](https://longbridge.com/zh-HK/news/268720790.md)
- [InSilico Out-licensed Drug ISM4808 Begins Clinical Trial](https://longbridge.com/zh-HK/news/278010381.md)
- [09:45 ETMedical Knowledge Group Appoints David Margines to Board of Directors, Advancing Its Legacy in AI- and Analytics-Driven Drug Commercialization](https://longbridge.com/zh-HK/news/278896967.md)
- [The Bull Case For Daiichi Sankyo Company (TSE:4568) Could Change Following ENHERTU’s Priority Review Success](https://longbridge.com/zh-HK/news/278992959.md)
- [Cocrystal Initiates Phase 1b Norovirus Antiviral Challenge Study](https://longbridge.com/zh-HK/news/278398168.md)